Sutro Biopharma Price to Free Cash Flow Ratio 2017-2021 | STRO

Historical price to free cash flow ratio values for Sutro Biopharma (STRO) since 2017. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Sutro Biopharma Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2022-01-21 10.07 0.00
2021-09-30 18.89 $-2.44 0.00
2021-06-30 18.59 $-2.18 0.00
2021-03-31 22.76 $-2.17 0.00
2020-12-31 21.71 $-2.30 0.00
2020-09-30 10.05 $-2.10 0.00
2020-06-30 7.76 $-2.45 0.00
2020-03-31 10.20 $-2.93 0.00
2019-12-31 11.00 $-2.98 0.00
2019-09-30 9.09 $-37.44 0.00
2019-06-30 11.38 $0.34 33.54
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.462B $0.043B
Sutro Biopharma Inc. develops and manufactures pharmaceutical products. The Company provides antibody drug conjugate and multi-specific antibody-based therapeutics for cancer therapy. Its product pipeline consists of STRO-001 and STRO-002 which are in clinical stage. Sutro Biopharma Inc. is based in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $143.345B 9.06
Bio-Rad Laboratories (BIO.B) United States $18.101B 36.73
QIAGEN (QGEN) Netherlands $11.301B 19.14
Biohaven Pharmaceutical Holding (BHVN) United States $7.598B 0.00
Emergent Biosolutions (EBS) United States $2.503B 9.00
Arcus Biosciences (RCUS) United States $2.274B 0.00
Myovant Sciences (MYOV) United Kingdom $1.296B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.081B 0.00
Zymeworks (ZYME) Canada $0.538B 0.00
SQZ Biotechnologies (SQZ) United States $0.203B 0.00
Ambrx Biopharma (AMAM) United States $0.201B 0.00
Enzo Biochem (ENZ) United States $0.155B 20.00